
A biologia sintética integra princípios de engenharia e biologia molecular para projetar, construir e modificar sistemas biológicos com novas funções. Envolve a montagem de partes genéticas padronizadas, a construção de circuitos genéticos sintéticos e a reprogramação do metabolismo celular para criar organismos ou componentes biológicos personalizados. As técnicas incluem edição genômica, síntese de DNA e otimização de vias metabólicas para desenvolver aplicações em terapêutica, biocombustíveis, biossensores e biofabricação. Este domínio aprofunda a compreensão da complexidade biológica por meio da criação de sistemas ortogonais, células mínimas e redes regulatórias sintéticas. A seguir, apresentamos uma compilação de publicações e patentes recentes que detalham inovações em ferramentas, metodologias e aplicações dentro da biologia sintética:
Esta é a nossa mais recente seleção de publicações e patentes mundiais em inglês sobre Biologia Sintética, provenientes de diversos periódicos científicos online, classificadas e focadas em circuitos genéticos, engenharia metabólica, síntese de DNA, edição genômica, CRISPR Cas9, genoma sintético, biobrick, componentes genéticos, engenharia de proteínas, chassis celulares, biossensores, otimização de vias metabólicas, controle da expressão gênica, promotores sintéticos, dispositivos de RNA, células mínimas, sistemas ortogonais, interruptores genéticos, operons sintéticos, vias metabólicas, evolução dirigida, redes regulatórias sintéticas, montagem de DNA, sistemas acelulares, transcrição sintética, expansão do código genético, biologia sintética, análise de fluxo metabólico, genes sintéticos e estratégias de biocontenção.
Probe design and electrochemical biomarker detection utilizing reusable polypeptide nucleic acid (pna) based sensors
Patent published on the 2026-05-21 in WO under Ref WO2026107321 by UNIV UTAH RES FOUND [US] (Kim Younghwan [us], Mohanty Swomitra Kumar [us])
Abstract: A biosensor apparatus includes an electrode comprising a surface including at least one of (i) a metal; and (ii) a layer of nanotubes. A plurality of peptide nucleic acid (PNA) probes are complexed to the surface of the electrode. The plurality of PNA probes are structured to bind to one or more biomarkers.[...]
Our summary: This study focuses on designing a biosensor using polypeptide nucleic acid (PNA) probes for electrochemical biomarker detection. The biosensor apparatus features an electrode with a metal surface or nanotube layer. PNA probes are attached to the electrode to selectively bind to specific biomarkers.
biosensor, peptide nucleic acid, electrochemical detection, probe design
Patent
Genetically modified aspergillus niger strain for production of citric acid and gluconic acid and methods
Patent published on the 2026-05-21 in WO under Ref WO2026105152 by DAFFODIL BIOCHEM LLP [IN] (Patel Kushal Jitu [in])
Abstract: A genetically modified strain of Aspergillus niger designated MTCC 25758 derived from parent strain Aspergillus niger ATCC 9142 through chemical mutagenesis using ethyl methane sulfonate at 1 mg/mL for 180 minutes demonstrates enhanced production capabilities for both citric acid and gluconic acid. The modified strain exhibits genetic modifications at 64 specific sequence positions that contribute to improved metabolic pathways, enhanced substrate utilization efficiency, and increased tolerance [...]
Our summary: A genetically modified Aspergillus niger strain MTCC 25758 shows enhanced production of citric acid and gluconic acid. Genetic modifications improve metabolic pathways and substrate utilization, resulting in higher yields. The strain maintains GRAS status while offering economic advantages in fermentation processes.
genetically modified organism, Aspergillus niger, citric acid production, gluconic acid production
Patent
Aspergillus niger mutant strain for production of citric acid and gluconic acid and methods
Patent published on the 2026-05-21 in WO under Ref WO2026105146 by DAFFODIL BIOCHEM LLP [IN] (Patel Kushal Jitu [in])
Abstract: An Aspergillus niger mutant strain designated MTCC 25759 derived from parent strain Aspergillus niger ATCC 9142 through chemical mutagenesis using ethyl methane sulfonate at 1 mg/mL for 30 to 60 minutes demonstrates enhanced production capabilities for both citric acid and gluconic acid. The mutant strain exhibits genetic modifications at 47 specific sequence positions that contribute to improved metabolic pathways, enhanced substrate utilization efficiency, and increased tolerance to acidic fer[...]
Our summary: The Aspergillus niger mutant strain MTCC 25759 shows enhanced production of citric acid and gluconic acid. Genetic modifications improve metabolic pathways and substrate utilization efficiency. The strain achieves 198.836 g/L gluconic acid and 0.415 g/L citric acid, offering economic advantages while maintaining GRAS status.
Aspergillus niger, mutant strain, citric acid, gluconic acid
Patent
System and method for real-time ai-based medical recommendations
Patent published on the 2026-05-21 in US under Ref US20260142030 by BOYD TIMOTHY [SE] (Gream Bianca [se], Boyd Timothy [se])
Abstract: [0000] A system for generation of medical recommendation based on patient-related data, including a processor of a medical recommendations server (MRS) node configured to host a machine learning (ML) module and connected to a patient entity node and to at least one medical emergency entity node over a network and a memory on which are stored machine-readable instructions that when executed by the processor, cause the processor to: acquire sensory data from a plurality of biosensors encapsulated [...]
Our summary: The system generates medical recommendations using patient-related data. It employs a machine learning module to analyze sensory and patient data. The recommendations are based on historical patient engagements and feature vectors derived from key classifying features.
real-time recommendations, machine learning, biosensors, artificial neural networks
Patent
Device for autonomous measurement in complex samples and for the autonomous extraction of a liquid sample
Patent published on the 2026-05-20 in EP under Ref EP4745572 by HEDBERG ELLINOR [SE] (Roxhed Niclas [se], Stemme GÖran [se], Ribet Federico [se], Hedberg Ellinor [se], GarcÍa Carmona Laura [es], Lucas Garrote Beatriz [es], Vegas GarcÍa Marta [es], GarcÍa Pellicer Marta [es], Quijano LÓpez Alfredo [es])
Abstract: Lateral flow strip for the autonomous realization of chemical and/or biological reactions in a complex liquid sample comprising at least one porous hydrophilic layer, with at least one zone of placement of the liquid sample, where the lateral flow is configured to transport the fluid along the porous hydrophilic layer, characterized in that it includes means of regulating the flow velocity of fluid along the lateral flow strip, configured to regulate the reaction time of the liquid sample in the[...]
Our summary: The device enables autonomous measurement and extraction of liquid samples. It features a lateral flow strip for conducting chemical and biological reactions. The system includes flow regulation and a biosensor for target molecule interaction.
autonomous measurement, lateral flow strip, biosensor, capillarity extraction
Patent
Production and medical use of psilocybin and related compounds
Patent published on the 2026-05-14 in AU under Ref AU2024350564 by PSYLINK UAB [LT] (Čiplys Evaldas, Korsakova Laura Martinkute, Žitkus Eimantas)
Abstract: The present invention provides a method for producing a target alkaloid from a precursor via a metabolic pathway in a recombinant yeast cell, wherein the metabolic pathway comprises a psiH enzyme, a psiK enzyme and a psiM enzyme, the method comprising culturing the recombinant yeast cell in a culture medium comprising the precursor under conditions suitable to allow the precursor to enter the recombinant host cell such that the recombinant yeast cell produces the target alkaloid, wherein the pre[...]
Our summary: This invention outlines a method for producing psilocybin using recombinant yeast cells. It involves a metabolic pathway with specific enzymes to convert a precursor into the target alkaloid. Additionally, it covers related compounds and their medical applications.
psilocybin, recombinant yeast, metabolic pathway, pharmaceutical compositions
Patent
Re-evaluating the site-directed nuclease classification as a regulatory trigger for genome-edited plant products
Published on 2026-03-05 by Osman Mewett, John McMurdy, Lieselot Bertho, Ana Atanassova, Naomi Stevens, Scott Huber, Maria Fedorova, Kevin Diehl, Kevin Tianmeng Zhao @NATURE
Abstract: Nature Biotechnology, Published online: 05 March 2026; doi:10.1038/s41587-026-03028-0Site-directed nuclease (SDN) classification into SDN-1, SDN-2 and SDN-3 outcomes is used for regulating genome-edited plant products in some countries. This reductive categorization system fails to cover the breadth of genome editing technologies developed over the past decade and their rapidly approaching commercial use. Here, we argue that, in the context of plant breeding, regulations should focus on the char[...]
Our summary: The current classification of site-directed nucleases (SDNs) is inadequate for regulating genome-edited plants. A shift towards an outcome-focused regulatory approach is proposed to enhance oversight and efficiency. This change aims to address challenges in crop improvement related to climate change and pest resistance.
genome editing, site-directed nucleases, regulatory framework, plant breeding
Publication
Ethical and Clinical Best Practices for Genome Editing Applications
Published on 2026-02-02 by Mara Ortiz-Bueno, Federica Zinghirino, Pilar Puig Serra, Kyriaki Paschoudi, Lluis Montoliu, Erden Atilla, Yonglun Luo, Alessia Cavazza, Carsten W. Lederer, Karim Benabdellah @MDPI
Abstract: Genome editing (GE) has transformed medicine by allowing precise changes to DNA, offering potential treatments for a range of inherited and acquired disorders. Several technologies support these advances, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)-based systems, of which the latter has emerged as the most accessible, versatile, and popular. While GE holds great promise, i[...]
Our summary: Genome editing technologies enable precise DNA modifications for medical treatments. Ethical and regulatory considerations are crucial for safe clinical applications. Regulatory agencies provide guidance on safety, consent, and compliance in genome editing practices.
Genome Editing, Ethical Standards, Regulatory Compliance, Clinical Applications
Publication